Supernus expands MERGE partnership as AI-powered agency of record
Supernus Pharmaceuticals expands its seven-year partnership with MERGE, appointing the agency as Agency of Record for QELBREE and its full digital ecosystem. The agreement leverages AI-driven strategies to enhance omnichannel marketing for Supernus' CNS portfolio, including treatments for Parkinson's disease and ADHD.
*this image is generated using AI for illustrative purposes only.
Supernus Pharmaceuticals has expanded its partnership with MERGE, appointing the marketing and technology agency as its Agency of Record (AOR) for QELBREE and its full digital ecosystem. This strategic move, announced on June 17, 2026, aims to unify Supernus' digital marketing and technology platforms through an AI-first approach to enhance healthcare communication experiences.
Under the expanded agreement, MERGE will lead omnichannel marketing strategy and assume responsibility for Supernus' digital ecosystem, including website development and CRM operations. The agency will also support two sales forces with execution resources. The partnership extends beyond Supernus' existing Parkinson's portfolio to include QELBREE (viloxazine extended-release capsules), a non-stimulant treatment for ADHD.
MERGE will continue to drive marketing efforts for Supernus' Parkinson's disease brands: APOKYN (apomorphine hydrochloride), GOCOVRI (amantadine extended-release capsules), and ONAPGO (apomorphine hydrochloride). The agency will utilize its Contextual Spectrum technology to deliver compliant, personalized digital interactions and tailored brand information to appropriate audiences.
The collaboration builds on a seven-year relationship between the two companies. Rebecca Lannan, Vice President of Marketing at Supernus, highlighted MERGE's consistent delivery of innovative strategies and high-quality execution as key factors in the decision to expand the partnership. Pat McGloin, Managing Director at MERGE, emphasized the natural extension of their successful partnership to manage the digital ecosystem and QELBREE.
Key Assignments Under the Expanded Agreement
| Brand / Portfolio | Treatment Area | Responsibility |
|---|---|---|
| QELBREE | ADHD | Agency of Record (AOR) |
| APOKYN | Parkinson's disease | Marketing support |
| GOCOVRI | Parkinson's disease | Marketing support |
| ONAPGO | Parkinson's disease | Marketing support |
| Digital Ecosystem | All portfolios | Website development, CRM operations |
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, including epilepsy, Parkinson's disease, and ADHD. MERGE is a marketing and technology agency recently awarded Agency of the Year by Modern Healthcare and Ad Age, specializing in the intersection of health and wellness.
How will the AI-first approach to QELBREE's marketing differentiate Supernus in the competitive non-stimulant ADHD market?
What specific metrics will Supernus use to evaluate the success of the unified digital ecosystem and CRM operations over the next fiscal year?
Could this expanded partnership signal a broader strategic shift by Supernus towards outsourcing more of their commercial infrastructure to specialized agencies?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
